0001558370-24-013882.txt : 20241030 0001558370-24-013882.hdr.sgml : 20241030 20241030070735 ACCESSION NUMBER: 0001558370-24-013882 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 241407426 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 bpmc-20241030x8k.htm 8-K
0001597264false00015972642024-10-302024-10-30

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

​

Date of Report (Date of Earliest Event Reported): October 30, 2024

​

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

​

Delaware

    

001-37359

    

26-3632015

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

​

45 Sidney Street
Cambridge, Massachusetts

    

02139

(Address of principal executive offices)

 

(Zip Code)

​

Registrant’s telephone number, including area code: (617) 374-7580

​

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

​

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

BPMC

Nasdaq Global Select Market

​

​

​

​

Item 2.02  Results of Operations and Financial Condition.

On October 30, 2024, Blueprint Medicines Corporation announced its financial results for the quarter ended September 30, 2024 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

​

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

​

Item 9.01  Financial Statements and Exhibits.

​

(d) Exhibits.

​

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

​

Exhibit No.

   

Description

99.1

​

Press release issued by Blueprint Medicines Corporation on October 30, 2024

104

​

Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

​

​

​

​

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

 

BLUEPRINT MEDICINES CORPORATION

 

 

 Date: October 30, 2024

By:

/s/ Kathryn Haviland

 

 

Kathryn Haviland

 

 

Chief Executive Officer

​

​

​

​

​

 EX-99.1 2 bpmc-20241030xex99d1.htm EX-99.1

EXHIBIT 99.1

​

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

​

-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 --

-- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 --

-- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end --

​

​

CAMBRIDGE, Mass., October 30, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.

​

“With another strong quarter of AYVAKIT revenue performance, our year-to-date results provide the foundation to drive significant growth and long-term shareholder value creation in 2025 and beyond. AYVAKIT’s sales momentum has given us the confidence to raise our revenue expectations again this year, estimating that we will end the year between $475 million and $480 million dollars. Ending our first full year of launch at nearly half a billion dollars in revenue positions AYVAKIT to be one of the most successful rare disease launches to-date,” said Kate Haviland, Chief Executive Officer of Blueprint Medicines. “AYVAKIT has demonstrated tangible benefits to patients globally, with long-term data further reinforcing the clinically meaningful benefits and well-tolerated profile of a disease-modifying treatment. AYVAKIT’s strong revenue ramp coupled with disciplined investment in our most compelling product opportunities, places Blueprint Medicines in a position to realize the significant decline in cash burn this year, while maintaining our focus on long-term growth and value creation.”

​

Third Quarter 2024 Highlights and Recent Progress

​

Mast cell disorders

​

●Achieved AYVAKIT net product revenues of $128.2 million for third quarter of 2024, including $113.1 million in the US and $15.1 million ex-US, representing 136 percent growth year-over-year.
●Advanced the Phase 1 single ascending dose/multiple ascending dose healthy volunteer study of BLU-808, a highly selective and potent investigational oral wild-type KIT inhibitor, with best-in-class potential for chronic urticaria and other mast cell disorders. Data from the healthy volunteer study, including safety, pharmacokinetic and pharmacodynamic markers, are anticipated in early 2025.
●Presented data at the American College of Allergy, Asthma and Immunology (ACAAI) conference demonstrating the efficacy of AYVAKIT in patients with moderate and severe indolent SM (ISM) at baseline, and showing the significant disease burden of SM, highlighting the urgency to diagnose and treat. Read the presentations here.
●Hosting scientific seminar on mast cell franchise development with leading allergy and asthma expert Dr. Paul O’Byrne on Thursday, November 14, 2024.

​

2024 Financial Guidance

​

Blueprint Medicines now anticipates approximately $475 million to $480 million in global AYVAKIT net product revenues in 2024, an increase from the previous range of $435 million to $450 million. This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger than expected performance outside of the U.S. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a

durable capital position to achieve a self-sustainable financial profile.

​

Key Upcoming Milestones

​

The company plans to achieve the following remaining milestones by the end of 2024:

​

Mast cell disorders

●Initiate registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM by the end of this year.

​

Cell cycle inhibition

●Continue strategic business development discussions.
●Complete Phase 1 combination dose escalation for BLU-222 by end of year to inform registration plans.

​

Third Quarter 2024 Results

​

●Revenues: Revenues were $128.2 million for the third quarter of 2024 generated from the net product sales of AYVAKIT/AYVAKYT. Revenues were $56.6 million in the third quarter of 2023, including $54.2 million of net product revenues from sales of AYVAKIT/AYVAKYT and $2.4 million in collaboration, license and other revenues.
●Cost of Sales: Cost of sales was $1.9 million for the third quarter of 2024, as compared to $2.8 million for the third quarter of 2023. The decrease was primarily due to lower sales to our collaboration partner in greater China.
●R&D Expenses: Research and development expenses were $85.3 million for the third quarter of 2024, as compared to $110.3 million for the third quarter of 2023. This decrease was primarily due to operational efficiency across our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development expenses included $12.6 million in stock-based compensation expenses for the third quarter of 2024.
●SG&A Expenses: Selling, general and administrative expenses were $89.9 million for the third quarter of 2024, as compared to $70.7 million for the third quarter of 2023. This increase was primarily due to an increase in activities supporting the commercialization of AYVAKIT/AYVAKYT. Selling, general, and administrative expenses included $15.7 million in stock-based compensation expenses for the third quarter of 2024.
●Net Loss: Net loss was $56.3 million for the third quarter of 2024, as compared to a net loss of $133.7 million for the third quarter of 2023.
●Cash Position: As of September 30, 2024, cash, cash equivalents and investments were $882.4 million, as compared to $767.2 million as of December 31, 2023. Blueprint Medicine’s cash and investments provide a durable capital position which, together with anticipated product revenues, the company believes will enable it to reach a self-sustainable financial profile.

​

Conference Call Information

​

Blueprint Medicines will host a live conference call and webcast at 8:00 a.m. ET today to discuss third quarter 2024 financial results and recent business activities. The conference call may be accessed by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring conference ID 387547. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

​

Upcoming Investor Conferences

​

Blueprint Medicines will participate in three upcoming investor conferences:

●Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 3:30 p.m. ET.
●Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:20 a.m. ET.
●Jeffries London Healthcare Conference on Thursday, November 21, 2024 at 12:00 p.m. GMT.

​

Scientific Webinar Series

​

●The second in our scientific seminar series, focused on mast cell diseases, to be held on Thursday, November 14, 2024 at 10:00 a.m. ET.

​

A live webcast of the above presentations and any related slides will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on the Blueprint Medicines website following the events.

​

About Blueprint Medicines

​

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

​

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines’ operations, including its expectations regarding growth and net product revenue in 2024; statements regarding its current or future approved drugs and drug candidates and operations, including plans to initiate registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM in 2024, complete Phase 1 combination dose escalation for BLU-222 to inform registration plans and continue strategic business development discussions by the end of 2024, and present healthy volunteer data from its Phase 1 trial for BLU-808 in early 2025; expectations related to the markets for current or future approved drugs and drug candidates, including expectations regarding the size or scale of patient opportunities that future approved drugs and drug candidates could address; the potential benefits of any of its current or future approved drugs or drug candidates in treating patients; statements related to liquidity and capital position, including expectations that its cash, cash equivalents and investments will provide a durable capital position which, together with anticipated product revenues, will enable Blueprint Medicines to reach a self-sustainable financial profile; and its financial performance, strategy, goals and anticipated milestones, business plans and focus, including expectations regarding its revenue ramp and continued decline in operating expenses and cash burn. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the risk that the marketing and sale of AYVAKIT/AYVAKYT or any future approved drugs may be unsuccessful or less successful than anticipated, or that AYVAKIT/AYVAKYT may not gain market acceptance by physicians, patients, third-party payors and others in the medical community; the risk that the market opportunities for AYVAKIT/AYVAKYT or Blueprint Medicines’ drug candidates are smaller than we estimate or that any approval we obtain may be based on a narrower definition of the patient population that we anticipate; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future

drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect its approved drugs or its current or future drug candidates, including affecting the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing and other arrangements; risks related to its liquidity and financial position, including the risk that Blueprint Medicines may be unable to generate sufficient future product revenues to achieve and maintain a self-sustainable financial profile; and the accuracy of its estimates of revenues, expenses and capital requirements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

​

​

Trademarks

​

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

​

​

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

​

​

​

​

​

​

​

​

September 30,

​

December 31,

​

​

2024

​

2023

Cash, cash equivalents and investments

$

882,353

​

$

767,171

Working capital (1)

​

597,187

​

​

593,470

Total assets

​

1,199,649

​

​

1,049,250

Deferred revenue (2)

​

12,034

​

​

5,604

Liability related to the sale of future royalties and revenues (2)

​

261,207

​

​

441,625

Term loan (2)

​

386,569

​

​

238,813

Total liabilities

​

886,501

​

​

918,641

Total stockholders’ equity

​

313,148

​

​

130,609

​

(1)   Blueprint Medicines defines working capital as current assets less current liabilities.

(2)Includes both current and long-term portions of the balance.

​

​

Blueprint Medicines Corporation

Condensed Consolidated Statements of Operations Data

(in thousands, except per share data)

(unaudited)

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

​

​

2024

​

2023

​

2024

​

2023

Revenues:

​

​

​

​

​

​

​

​

​

​

​

​

Product revenue, net

​

$

128,184

​

$

54,228

​

$

334,825

​

$

133,173

Collaboration, license and other revenue

​

​

—

​

​

2,338

​

​

27,633

​

​

44,250

Total revenues

​

​

128,184

​

​

56,566

​

​

362,458

​

​

177,423

Cost and operating expenses:

​

​

​

​

​

​

​

​

​

​

​

​

Cost of sales

​

​

1,932

​

​

2,782

​

​

12,716

​

​

8,280

Collaboration loss sharing

​

​

—

​

​

1,771

​

​

—

​

​

4,301

Research and development

​

​

85,300

​

​

110,252

​

​

257,761

​

​

330,184

Selling, general and administrative

​

​

89,926

​

​

70,741

​

​

262,822

​

​

215,826

Total cost and operating expenses

​

​

177,158

​

​

185,546

​

​

533,299

​

​

558,591

Other income (expense):

​

​

​

​

​

​

​

​

​

​

​

​

Interest expense, net

​

​

(7,616)

​

​

(3,808)

​

​

(20,376)

​

​

(13,624)

Other income (expense), net

​

​

587

​

​

(728)

​

​

962

​

​

(369)

Debt extinguishment gain

​

​

—

​

​

—

​

​

173,676

​

​

—

Total other income (expense), net

​

​

(7,029)

​

​

(4,536)

​

​

154,262

​

​

(13,993)

Loss before income taxes

​

​

(56,003)

​

​

(133,516)

​

​

(16,579)

​

​

(395,161)

Income tax expense

​

​

273

​

​

197

​

​

554

​

​

907

Net Loss

​

$

(56,276)

​

$

(133,713)

​

$

(17,133)

​

$

(396,068)

Net Loss per share — basic and diluted

​

$

(0.89)

​

$

(2.20)

​

$

(0.27)

​

$

(6.55)

Weighted-average number of common shares used in net loss per share —basic and diluted

​

​

63,381

​

​

60,688

​

​

62,608

​

​

60,445

​

Media Contact 

 

Andrew Law

617-844-8205

media@blueprintmedicines.com

 

Investor Contact 

 

Jenna Cohen

857-209-3147

ir@blueprintmedicines.com

 EX-101.SCH 3 bpmc-20241030.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bpmc-20241030_lab.xml EX-101.LAB EX-101.PRE 5 bpmc-20241030_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Oct. 30, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 30, 2024
Entity File Number 001-37359
Entity Registrant Name Blueprint Medicines Corporation
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-3632015
Entity Address, Address Line One 45 Sidney Street
Entity Address, State or Province MA
Entity Address, City or Town Cambridge
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 374-7580
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BPMC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001597264
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bpmc-20241030.xsd bpmc-20241030_lab.xml bpmc-20241030_pre.xml bpmc-20241030x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bpmc-20241030x8k.htm": { "nsprefix": "bpmc", "nsuri": "http://www.blueprintmedicines.com/20241030", "dts": { "schema": { "local": [ "bpmc-20241030.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "bpmc-20241030_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20241030_pre.xml" ] }, "inline": { "local": [ "bpmc-20241030x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_10_30_2024_To_10_30_2024_8eAb9CPbVU6hUXjAjB9RpQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bpmc-20241030x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_30_2024_To_10_30_2024_8eAb9CPbVU6hUXjAjB9RpQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bpmc-20241030x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001558370-24-013882-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-013882-xbrl.zip M4$L#!!0 ( /$X7EEC]2C>F0, /@, 1 8G!M8RTR,#(T,3 S,"YX M]Z=9&DJ+9;H$"21=(6R"W!46-;;84I26IVOGW M'=*B;,J2XRS:4QR^-X^/,YRA+M]N2T%^@-*\DE>3+$XG!"2K"BY75Y-&1U0S MSB=OKU^^N'P510\W][>DJ%A3@C2$*: &"K+A9DV^5'5-);D#I;@0Y$;Q8@6$ M9&G\)D[C^06)HE;DAFH,JB1Q:M,XZY"_6L%*+C PF:7)-)W^0;)%=K'(_B3O M[CKF'3I<\J>I6UTL-%M#28FA:@7F$RU!UY3!U61M3+U(DLUF$^>B@5IQ:4HH M..,2=,RJTDEFZ0QS0HU1/&\,?*A4^1Z6M!$&\R/_:ZAP1C!M FQ6 L(!C'F6 M>H%^@HTWL[A2*]PHS9*'N]O/SJHG%\ [\C97(M; XE7U(T' >?-$K-.*TKHC M+ZG.G6X+!&2M3&0>:]#'] [JJZM*#/$]$M 5+(,C.N?M(5\GB':Y0* PX0E; MWD6R SV5-4KAM7P<3H=' QM;,>IBECS<R/9Z* @@%6- M-&K,^0X,TVW4J/-Y@NB!E4$3@9K @YY(A(5S[$=/ARU;#UNU2"_!?>GV,F?S M^3QQ:.>4LV%1!/I7;>1J>B2@2UC9>7$B7;8>24OKW)A:C=A!)-C@C+;W?A&5XO^T$XH/CZ?5N//%NY&WK84T$PNDAOXWBF)B!PQV'[2W%7-B)T+L?]VC$]FE*)OB>(YQ:^_WM(WAC[(S#?@ N_/% M,_<\_M0=VE2/T>T/=S_VV^Z*L%.Y_@E02P,$% @ \3A>66:CF>)>!0 MUSL !4 !B<&UC+3(P,C0Q,#,P7VQA8BYX;6S5F^%OXC88QK]/VO_PCGW9 M21="Z*JMJ.V)O=]8\_7/[D M.%]N/@\AI,%J@0B'@"&?HQ#6F,]A3)=+G\ ]8@Q'$=PP',X0@-=I_][NM"_. MP7$RDQL_%H,H@<2MV_;RRB SI*0G!KIG';?;Z?X*7L\[[WF_0?\^5]Z+A%.\ M7QIA\E]/_IB(24'T2N+>)L97K3GGRY[KKM?K]OJL3=E,C.]X[I?[X2B8HX7O M8!)SGP2H!4+?BY,7AS3P>;)0.\,W$Q8I@S,WG\NHD+\Y2N;(EQROZYQY[4T< MMK*(LGS )$HNJR'/!^R*S]VTF$M?6&?M>Q<7%VY2;8F% \B6SI^@:"B.("GU M^':)KEIHPQ$)D8R;O,IHA"KBRK+[["R]:5 PC.3"4J;\Y@Q-4[]8M1.CH#VC M3VZ(!FDP<[EF)3.$&5)"UY$[BJ(9/&5WHHZ;344WQ:S2)ZO=2:(2AF*Y8 OSA M;^IN?M-:YQF%0IY5$''^''U'Z.O$#?Y1?O]>IO/^GS"]S\YQ8^&HZ:]4MA@E M72.*I-V:I2!I(];E2)F!=&L0HD?$, UO2?A>7-TJFBSK3@ K;6MEO@HBRT'3 M9SV:N-06A"](XP;@NR4<\^T''*%/J\4$,4W/&HG%R)D:4K25ZY:"9HQ9E['4 M$*0CI):-T?49S;"\)A/^R5_HSFP&F?64Z1LKDE;46$V;(>J1Q#V[@K1MC+H[ ML3]E2\J2K=B(B]/I@*X(9]L!#EOQ(@ N3O(5D M&J ,LJE SM48U6-_*6P4\Q>F'#'LNVV:]]23O:;7(L$%L-;W[,A_)K;"' MHG_3%_Y^&(I5B[-_AI@@S[@8>JWUD%:T6 14([0:SJJ\1X*9>;Y5!R#=X8$T M=Q;-)DY.Y0_LD=$G3 +S38%1?BIX&AK5$EK2G@*DILBOQ6E^R5"IXOV].2^2P[!2@U:5^+1VDM<93F3:/X2&/N1W_C9>4VRB ^ M%2"U36J9+"A/ 4M]X-F*)*/[*/'.27FC\$U$HMI,C6DB"K7+:7*&+,N68DA)([-[8;_ M8IAS1 9TL5B1;"\>:[HUZ2SFK+(U!9M69"EQU5GK8I>Y0M&V ?1&-,(!YIC, M[L4>AF%?U[-69#%TYJ84<2\5EN)6$;0N:\^6H#P; .V1(0DW$F]<\DT,^DYI"X-X_F71RO$/LN0'5# M3@=38\,&6%_H3P-9<^Q7 S>=HFE^1RA8B?N'K=>=C#&/=-MTFF(O(R/"=+X/,8K"J&BN?N78UEF)6&;7VWB,S!>7: M['>^;A>(S03M'QE=\[FX.5CZ9&O\1-RDMIC! ]HL/J;02BTE\I#$1SZH4.:0 MND-FWQB@ W$7R?SH3MP_;OY 9C1?ZJR'TM!:$<>2R&H035F/1#"SA<07A'$# M\/7%[B64.Y@/D3_3-%RN6PR;MA4%6:%H*5SZC'6ARMU VNVB=.D^SSP41_+O M7+.7LM'7WP!02P,$% @ \3A>64)U*_V0! IR8 !4 !B<&UC+3(P M,C0Q,#,P7W!R92YX;6S5FEUSVC@4AN]W9O^#UGOM3R $)K1#:+K#-#1,0J>= MO>D(6X!F; ZUJWE6+T.,,TTR3WD\B)*0)+-L]S#R"A-2$E? M7FBW'-MSO#9P^VZG[W;!<'*(G$B%"WPY-,3DG[[Z,YV7&O+ R.5J(8KW$2'JU%\)OZHEGU\+G_J@=OK M]>QDU)#N 7#':(B>T0(DY_IB%Z.!P7$4ARI71K4+M M:EF3*BOY9^_+C!GB,EMR^:,<3&M3M_R_I1T9B;8"D0 %A[-8J/LYCM-S@ ET MHN-#2 *PSPK^6\5)O;+BD/H9+:&:VI1EJ:IT7.9+$C#M'G=31'K(# :4ASS*^D//6]=0W?G]$2*^E$?(91T>PO"FN:_Q74IPS: MUV PECM7%E.6./8BC4,CNB:"[48T*$=R]JJF$7I[,2FPSC6 S>!V',B"Y5Y^ MO[.^L'*5Q#<-TEO*2/'<7 //, BD=SS])S?&R"U%4Q#;-"Q52TB1=*^()'EG M/[$IHZ]XW]B=I7(2WE P5:I(V=Q>D.SVX!BH(;BN1R#;I)=.K%HN;*D"%8 N)XN#G67U2MS:ZY)5=/*L/I MBI+R7O TI#FF5U*NC:^Y"?_*L!"(C&@4K4FZN^,%[A?&90MIN1VO]XLBJ"Y? M<\@WY3'#5*;9)0]*?BJ4%QIB'PM,EA.Y@V!8W3U')!_4'!P5M6L6^>:\/A93 MAM2L07(#ESS*5$_ V=-B4;A&E0]ECF25#(9C^2&V_83*F9S$ M-8U&%?F:0\T-^5#N)0*UG_@8PF6!_YGQK/"V%.[]HKY?EJW]+NO#[^S3']^H MWVW9>W_P_ENYYXRN:Z$O%"@Z/@N1<5 ! MY674^<)*VY162HMM$?#7WYVTA191U%%'SSAKC=HF37;V6_9;T]W_3H M;[G.UR]"AO^"B*.YNN7TOWXIMRNUVI?_[OUG]W\X#ED7^ZT3I+O:>$B< &D> MP0'1T<0*S!+JN*,1=E"=>)YEVVC?L_0^B1X1^$PQPV<4&7%<--8^]N%1URG% M73+"HK$2C4R;!3XK\5F1%W-(* ER21!0N;[H&CY]8JD>]F;Q.N I.ATO%C*B M*"O+O=O$N[$T@HY<%=4.2D@L*&HA+VHY.%!@;N1MAQWFDRF60F4L;U M^EE!493LE X6=2K9EC-(]61#TKXBSTM9VJP"QN+NTSO]4R/3UKBK.AIJJ9ZJ M/28CSW*"(=$MS7*(G]'<(0-9X"5^/@4 H ?I)4;PR-FP<=YUY2*AHY"]J)^T M-9,,,6Y#OB E!HJ[>\2XEUCY++0FD6@]0-;C;^'0ZE MNOIL;U>W;I ?S&SR=6.(O;[E<($[*DG\*-B!2;/0G.JC6_[(QK.2XSJ$=K"F M)3H:\<(_+5TG#OL3.C1 #7B6%@(U#5H4*0=CC^&X)_ ]B>]1INIUW.15D915 MI7*J_NCFS>[%5?EJ7VF-SC:0@X=T?F*5J@XL9%:!=7K8KCDZF1Z3V0:R]*\; M':T7G)JF.6K5@V[>.QF=7!ZW9[Q1[HD]86./!Y:3E8*8S^UF4S"^-LAE4(@Z M58K?;-R?@SKV>=&;WIYRW?9QIV,T_.+%3"WW) JJ@6V?W($RFT8RB9LHT7S=\:SBR"664[-*8[-)W MQQZ[8LQ:BE##UO!LU,2#$4;*^,K2Z;5A$0^QA9"5PE^I':KG%+?!U/DDTA*\;L')79A-S< MD;$AGG(32X=-4^#YOW=&6*>;+6<3(RC)F6)Q<F"!LU;&N;M ?Z/R2R)[=V MAC"82=AH@IR1Q5"?).!)+4N@LZ57%=ZZ9T8&#HR'&1OV)%G A9PL]Y0\+_9R MDD)ZJE3(]0I"7M$,)<<+14RU&=[;'<7S&T :SL!#RYZ5OG2L(?%1@TQ0RQUB MY\MV> =^^T!0X\L.Z^U;MR0-*J S<(G.8=OJ.R4-&)%X.ZKK M <'GSU \(=^U+1W]Q;-_<0^F@5-#(KB8A\E77UF/B M1C/GHH':GW*FV=[/J.P6S7:UT6[5.K=I&Y<8!JEY4OI<;AU54:=;K MM7:[UFS\5MC3P)YCWP2I"UQG&QUD*AG0/W).F0.8T#?/!E'*R O]&+$A4XX) M#9<1%#)*93P><:7RHXJ!S^1AJL3 H=((+;(8 M<0B/ W=AP(4_WUZ8?Z/L%G^1L;XU6_5__A+R_ YCIM=JM6\KO*B(@0U]>H[EB[[:P O+PZ_J6=@26M5& M![6JI\U6YQUM *=CSQ]C)T"!B]I$HPP2BJT@(==#@KRI;R7D^'T [1HH, F% M=^P!3\.\U:EF8J=/4%D+$#0+BI1[88 _*E]2_XJBI$5&KA>@S?BZBL'#(GZ MJC@P:T)!C_J"4=!S=R?];E!M]:^\&1WP[4R1K&WX^#UJ@>1ZU1 MQ?5 )3!P[Y6#-R']9G6*0:U3#%#%Y-Q2CI]/H5$X6E9Z:UXH]0Q$*DHX-(NA&%)C"<53XQ_36 M&M6T?75PWC>+@^9-OE66)SVAQR_W/ 9 ?IY\:YK5X453DG-UOUWOG$%/<;EG MT_PFU_-'G=L!$ 59O,:1N&H8"N-A[YI!3_D<0DQ45$ M:AHEC!(/J= B(V$JKLCNI )_=^-^]$Z:ZP(/_NLQ<#?$"RP-VQ$)@:.B[I+X M=Y*2T:@Q5=^&=U[9I* ),1J=#D#7N3=4GZ1MBE"SUAQMH?G:M'<%Y#3P9A57 M)_/DP\VQS,<\]Z/&.SAU3M 0CS!*R9>W5J-M ?(%@H M2Q'-WH!D*0*%UM_=GX^ ^]_/:,M\],VR"

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end XML 16 bpmc-20241030x8k_htm.xml IDEA: XBRL DOCUMENT 0001597264 2024-10-30 2024-10-30 0001597264 false 8-K 2024-10-30 Blueprint Medicines Corporation DE 001-37359 26-3632015 45 Sidney Street Cambridge MA 02139 617 374-7580 false false false false false Common stock, par value $0.001 per share BPMC NASDAQ